Cargando…
P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430320/ http://dx.doi.org/10.1097/01.HS9.0000973320.18602.7b |
| _version_ | 1785090934884532224 |
|---|---|
| author | Mei, Heng Zhou, Hu Hou, Ming Sun, Jing Zhang, Lei Luo, Jianmin Jiang, Zhongxing Ye, Xu Xu, Yajing Lu, Jun Wang, Hui Hui, Aimin Zhou, Yongchun Hu, Yu |
| author_facet | Mei, Heng Zhou, Hu Hou, Ming Sun, Jing Zhang, Lei Luo, Jianmin Jiang, Zhongxing Ye, Xu Xu, Yajing Lu, Jun Wang, Hui Hui, Aimin Zhou, Yongchun Hu, Yu |
| author_sort | Mei, Heng |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430320 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104303202023-08-17 P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL Mei, Heng Zhou, Hu Hou, Ming Sun, Jing Zhang, Lei Luo, Jianmin Jiang, Zhongxing Ye, Xu Xu, Yajing Lu, Jun Wang, Hui Hui, Aimin Zhou, Yongchun Hu, Yu Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430320/ http://dx.doi.org/10.1097/01.HS9.0000973320.18602.7b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Mei, Heng Zhou, Hu Hou, Ming Sun, Jing Zhang, Lei Luo, Jianmin Jiang, Zhongxing Ye, Xu Xu, Yajing Lu, Jun Wang, Hui Hui, Aimin Zhou, Yongchun Hu, Yu P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL |
| title | P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL |
| title_full | P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL |
| title_fullStr | P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL |
| title_full_unstemmed | P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL |
| title_short | P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL |
| title_sort | p1611: efficacy and safety of avatrombopag for the treatment of chronic immune thrombocytopenia in a chinese adult population：a multicenter, randomized phase iii trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430320/ http://dx.doi.org/10.1097/01.HS9.0000973320.18602.7b |
| work_keys_str_mv | AT meiheng p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT zhouhu p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT houming p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT sunjing p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT zhanglei p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT luojianmin p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT jiangzhongxing p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT yexu p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT xuyajing p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT lujun p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT wanghui p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT huiaimin p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT zhouyongchun p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial AT huyu p1611efficacyandsafetyofavatrombopagforthetreatmentofchronicimmunethrombocytopeniainachineseadultpopulationamulticenterrandomizedphaseiiitrial |